
MMED Stock Forecast & Price Target
MMED Analyst Ratings
Bulls say
Minimed Group is viewed favorably because its 2026 IPO and near-complete separation from Medtronic should remove technical overhangs and let fundamentals show through, while the company’s clean balance sheet and stand-alone focus support faster execution. Its unique “full-stack” diabetes platform—traditional pumps, CGMs, smart pens, and a proprietary pharmacy—helps deepen recurring revenue, improve retention, and capture growth in underpenetrated T1/T2 intensive-insulin markets, where penetration remains low. With new products already launching or nearing launch, revenue is modeled to grow from $3,102M in FY26 to about $4,097M by FY29E, while adjusted EBITDA margin expands from 15.5% to 20.8%.
Bears say
Minimed Group is burdened by a temporary but significant ownership overhang, since Medtronic still retains about 90% of shares after the March 2026 IPO, keeping trading dynamics and investor perception tied to Medtronic rather than a clean standalone profile. The company also faces meaningful execution risk from competitive pressure, limited traction in new product launches, and the possibility that existing patients switch to rival pumps, while a delay to the planned summer 2027 FIT patch pump launch could cede share to competing systems. In addition, dependence on Abbott for its exclusive CGM supply, potential pharmacy-channel economics challenges, GLP-1-related slowdowns in Type 2 adoption, and ongoing transition-service, royalty, and margin headwinds all point to a constrained growth and profitability ramp.
This aggregate rating is based on analysts' research of MiniMed Group Inc and is not a guaranteed prediction by Public.com or investment advice.
MMED Analyst Forecast & Price Prediction
Start investing in MMED
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About MiniMed Group Inc (MMED) Forecast
MMED Analyst Forecast & Price Prediction
Start investing in MMED
Order type
Buy in
Order amount
Est. shares
0 shares